Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Exparel has a proven efficacy in providing pain relief for up to 72 hours with a single-dose administration at surgical sites. The study aims to evaluate the effectiveness of endoscopically-guided injection of Exparel (Bupivacaine) for the treatment of craniofacial pain. This study would be conducted in a prospective, randomized, double-blinded, placebo- controlled, and cross-over fashion. We aim to investigate whether the administration of Exparel (Bupivacaine) to the lateral nasal wall may positively impact craniofacial pain and functional outcomes, in patients who experience relief with the topical application of Lidocaine (routinely given prior to almost all ENT endoscopy).
Sponsor: Stanford University
You may qualify if…
- ✓ Patients with a chief complaint of craniofacial pain (migraine, cluster headache, trigeminal autonomic cephalgia, sphenopalatine ganglioneuraligia, paroxysmal hemicrania) who has Stanford Pain \& ENT clinic visit
You may not qualify if…
- ✕ age \<18 or \>80
- ✕ pregnant women
- ✕ economically disadvantaged (not able to afford clinic visits/treatments)
- ✕ decisionally impaired (unable to obtain informed consent)
- ✕ has allergy to bupivacaine
- ✕ unable or unwilling to participate plans to participate in another clinical study at any time during this study
Where it's recruiting
Stanford
Source: ClinicalTrials.gov · NCT04930887 · last updated 2026-04-27